Rosiglitazone - CAS 122320-73-4
Catalog number: 122320-73-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Rosiglitazone is a potent antihyperglycemic agent and a potent thiazolidinedione insulin sensitizer with IC50 of 12, 4 and 9 nM for rat, 3T3-L1 and human adipocytes, respectively.
BRL 49653
Canonical SMILES:
1.Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness.
Ahuja V1, Chou CH2. Curr Diab Rep. 2016 Jun;16(6):47. doi: 10.1007/s11892-016-0744-4.
The number of available therapies for treating type 2 diabetes has grown considerably in recent years. This growth has been fueled by availability of newer medications, whose benefits and risks have not been fully established. In this study, we review and synthesize the existing literature on the uptake, efficacy, safety, and cost-effectiveness of novel antidiabetic agents. Specifically, we focus on three drug classes that were introduced in the market recently: thiazolidinediones (TZDs), dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Not surprisingly, we find that the usage trends reflect the efficacy and safety profile of these novel drugs. The use of TZDs increased initially but decreased after a black-box warning was issued for rosiglitazone in 2007 that highlighted the cardiovascular risks associated with using the drug. Conversely, DPP-4 inhibitors and GLP-1 receptor agonists gained market shares due to their efficacy in glycemic control as an add-on treatment to metformin.
2.Minimally invasive surgery for ICH evacuation followed by rosiglitazone infusion therapy increased perihematomal PPARγ expression and improved neurological outcomes in rabbits.
Wu G1, Wu J1, Wang L1, Jiao Y1, Zhou H2, Tang Z3. Neurol Res. 2016 Apr 15:1-8. [Epub ahead of print]
OBJECTIVES: To observe the effects of minimally invasive surgery (MIS) for intracerebral hematoma (ICH) evacuation followed by rosiglitazone infusion therapy on peroxisome proliferator-activated receptor-gamma (PPARγ), blood-brain barrier (BBB) permeability, and neurological function.
3.Chronic stress and rosiglitazone increase indices of vascular stiffness in male rats.
Goodson ML1, Packard AE2, Buesing DR3, Maney M2, Myers B2, Fang Y1, Basford JE4, Hui DY4, Ulrich-Lai YM2, Herman JP2, Ryan KK5. Physiol Behav. 2016 Mar 31. pii: S0031-9384(16)30117-2. doi: 10.1016/j.physbeh.2016.03.031. [Epub ahead of print]
Prolonged and/or frequent exposure to psychological stress responses may lead to deterioration of organs and tissues, predisposing to disease. In agreement with this, chronic psychosocial stress is linked to greater cardiovascular risk, including increased incidence of atherosclerosis, myocardial ischemia, coronary heart disease, and death. Thus the association between stress and cardiovascular dysfunction represents an important node for therapeutic intervention in cardiovascular disease. Here we report that 2weeks of chronic variable stress (CVS) increased indices of vascular stiffness, including increased collagen deposition in the aortic adventitia and increased resting pulse pressure, in male rats. Thus CVS may represent a useful rodent model for stress-associated CVD, especially for aging populations for which widening pulse pressure is a well-known risk factor. Additionally, we report that the thiazolidinedione Rosiglitazone (RSG) blunts chronic stress-associated increases in circulating corticosterone.
4.Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Raschi E1, Poluzzi E1, Koci A1, Antonazzo IC1, Marchesini G2, De Ponti F3. Nutr Metab Cardiovasc Dis. 2016 Feb 19. pii: S0939-4753(15)30192-7. doi: 10.1016/j.numecd.2016.02.006. [Epub ahead of print]
BACKGROUND AND AIMS: We tested the possible association between dipeptidyl peptidase-4 inhibitors (DPP-4-I) use and heart failure (HF) occurrence by assessing the publicly available US-FDA Adverse Event Reporting System (FAERS).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PPAR Products

CAS 22978-25-2 GW9662

(CAS: 22978-25-2)

GW9662 is a potent, irreversible and selective PPARgamma antagonist, which prevented activation of PPARgamma and inhibited growth of human mammary tumour cell ...

CAS 76541-72-5 SR 202

SR 202
(CAS: 76541-72-5)

SR 202 is a selective PPARγ antagonist used as an antidiabetic and antiobesity agent. SR 202 inhibits PPARγ-dependent adipocyte differentiation and growth in vi...

CAS 637-07-0 Clofibrate

(CAS: 637-07-0)

Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.

CAS 475479-34-6 Aleglitazar

(CAS: 475479-34-6)

Aleglitazar is a potent dual agonist of peroxisome proliferator-activated receptor (PPAR) α/γ.

CDDO Imidazolide
(CAS: 443104-02-7)

CDDO Imidozolide is a synthetic triterpenoid as Nrf2 signaling activator with highly active in suppressing cellular proliferation of human leukemia and breast c...

(CAS: 1680204-90-3)

CC-618 has been found to be a PPARβ/δ antagonist that could be used to study the potential biological activity of Cys249 at some extent. IC50: 10 μM.

CAS 108409-83-2 FH535

(CAS: 108409-83-2)

FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist.

CAS 313516-66-4 T0070907

(CAS: 313516-66-4)

T0070907 was identified as a potent and selective PPARgamma antagonist. T0070907 blocked PPARgamma function in both cell-based reporter gene and adipocyte diffe...

(CAS: 1168138-37-1)

PPARγ is a ligand-activated nuclear receptor and was reported to plays a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation...

SR 1664
(CAS: 1338259-05-4)

SR 1664 is a PPARγ (peroxisome proliferator-activated receptor γ ) inhibitor. SR 1664 can block PPARγ by cyclin-dependent kinase 5 with an IC50 value of 80 nM a...

CAS 476436-68-7 Naveglitazar

(CAS: 476436-68-7)

Naveglitazar is a Dual peroxisome proliferator-activated receptor gamma and alpha (PPARgamma and PPARalpha) agonist

CAS 331741-94-7 Muraglitazar

(CAS: 331741-94-7)

Muraglitazar is a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist(EC50s = 320 and 110 nM in vitro).

CAS 1217466-21-1 GW 1929 hydrochloride

GW 1929 hydrochloride
(CAS: 1217466-21-1)

GW 1929 hydrochloride is a selective and orally bioactive agonist of peroxisome proliferator-activated receptor (PPAR)γ (pEC50 = 8.05, < 4 and < 4 for human PPA...

CAS 213252-19-8 KRP297

(CAS: 213252-19-8)

KRP297, also called as L4 10198 or MK 767, is a Peroxisome proliferator-activated receptor (PPAR) alpha and gamma (PPARα and PPARγ) agonist. With potential to t...

CAS 111025-46-8 Pioglitazone

(CAS: 111025-46-8)

Pioglitazone significantly attenuates left ventricular (LV) cavity dilatation and dysfunction by echocardiography as well as LV end-diastolic pressure in mice w...

CAS 824932-88-9 GFT505

(CAS: 824932-88-9)

Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. It induces resolution of nonalco...

CAS 50892-23-4 Pirinixic Acid

Pirinixic Acid
(CAS: 50892-23-4)

WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.

CAS 1675-54-3 BADGE

(CAS: 1675-54-3)

BADGE is a PPARγ antagonist with selectivity over PPARδ and PPARα. It inhibits adipocyte differentiation, and induces apoptosis in cancer cells. BADGE also exhi...

(CAS: 1356497-91-0)

ST247 is a selective and inverse peroxisome proliferator-activated receptor (PPAR)β/δ agonist with IC 50 value of 19 nm, 10-fold more potent than GSK0660 with I...

CAS 49562-28-9 Fenofibrate

(CAS: 49562-28-9)

Fenofibrate (Tricor, Trilipix) is a compound of the fibrate class and fibric acid derivative.It is used alone or along with statins in the treatment of hypercho...

Chemical Structure

CAS 122320-73-4 Rosiglitazone

Quick Inquiry

Verification code

Featured Items